DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI

NCT ID: NCT07162506

Last Updated: 2025-12-12

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-08-01
• Study Completion Date: 2030-08-30

Brief Summary

This is a single-center, Phase II clinical study aiming to evaluate the efficacy, safety, and organ preservation feasibility of definitive concurrent chemoradiotherapy versus surgery in patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC) who achieve clinical complete response/partial response (cCR/PR) after neoadjuvant camrelizumab combined with chemotherapy.

A total of 120 eligible subjects will be enrolled. Patients with cCR/PR after 2 cycles of induction chemoimmunotherapy (camrelizumab + nab-paclitaxel + carboplatin) will be grouped based on personal willing: the control group (n=60) will receive radical esophagectomy + mediastinal lymph node dissection; the experimental group (n=60) will receive definitive concurrent chemoradiotherapy (radiotherapy: 50.4 Gy/28f; chemotherapy: nab-paclitaxel 175mg/m² + carboplatin AUC=5, q21d for 2 cycles). All the patients will receive camrelizumab maintenance therapy (200mg q21d) up to 1 year.

Conditions

Esophageal Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

DCRT

Definitive concurrent chemoradiotherapy (radiotherapy: 50.4 Gy/28f; chemotherapy: nab-paclitaxel 175mg/m² + carboplatin AUC=5, q21d for 2 cycles)

Group Type: EXPERIMENTAL

Radiotherapy

Intervention Type: RADIATION

Radiotherapy: 50.4 Gy/28f

Chemotherapy

Intervention Type: DRUG

Chemotherapy: nab-paclitaxel 175mg/m² + carboplatin AUC=5, q21d for 2 cycles

Surgery

Radical esophagectomy + mediastinal lymph node dissection

Group Type: ACTIVE_COMPARATOR

Surgery

Intervention Type: PROCEDURE

Radical esophagectomy + mediastinal lymph node dissection

Interventions

Surgery

Radical esophagectomy + mediastinal lymph node dissection

Intervention Type: PROCEDURE

Radiotherapy

Radiotherapy: 50.4 Gy/28f

Intervention Type: RADIATION

Chemotherapy

Chemotherapy: nab-paclitaxel 175mg/m² + carboplatin AUC=5, q21d for 2 cycles

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Volunteered to participate, cooperated with follow-up visits.

2. Aged 18 - 75 years (inclusive), male or female.

3. Histologically confirmed locally advanced resectable ESCC, clinically staged as Stage II - IVa (cT1N1-3M0, cT2-4aN0-3M0 before treatment; 8th AJCC), and achieve cCR/PR after 2 cycles of camrelizumab combined with nab-paclitaxel and carboplatin.

4. Presence of measurable and/or non-measurable lesions as defined by Japanese Classification of Esophageal Cancer (12th Edition);

5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.

6. Estimated survival time ≥ 3 months.

7. The function of major organs meets the following requirements:

1. Absolute neutrophil count (ANC) ≥ 1.5×10^9/L;

2. Platelets ≥ 80×10^9/L;

3. Hemoglobin ≥ 9g/dL;

4. Serum albumin ≥ 2.8g/dL;

5. Total bilirubin ≤ 1.5 × ULN, ALT, AST and/or ALP ≤ 2.5 × ULN;

6. Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 60mL/min;

7. International normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤ 1.5× ULN (subjects on stable doses of anticoagulation therapy, such as low molecular weight heparin or warfarin, and with INR within the expected therapeutic range of the anticoagulant can be screened);

8. Patients of childbearing potential must use a medically approved contraceptive method (such as intrauterine device, contraceptive pills, or condoms) during the study treatment period and within 6 months after the end of the study treatment; serum Human Chorionic Gonadotropin (HCG) or urine HCG test must be negative within 72 hours before study enrollment; and must not be breastfeeding.

Exclusion Criteria

1. Surgery for esophageal cancer;

2. Esophageal fistulae due to infiltration of the primary tumor；

3. Risk of gastrointestinal bleeding, esophageal fistula or esophageal perforation;

4. Poor nutritional status, weight loss of ≥10% in the previous 2 months, with no significant improvement after nutritional intervention;

5. Major surgery or severe trauma within 4 weeks prior to first use of study drug;

6. Uncontrollable pleural effusion, pericardial effusion, or ascites that requires repeated drainage;

7. Received or receiving any of the following treatments in the past:

1. Anti-PD-1 (except for camrelizumab) or anti-PD-L1 antibody therapy, chemotherapy, radiotherapy or targeted therapy;

2. Participation in a study of an investigational agent or device within 4 weeks before the first dose of study treatment;

3. Systemic treatment with corticosteroids (>10 mg prednisone equivalent dose per day) or other immunosuppressive agents is required for 2 weeks before the first dose of study treatment (except for the use of corticosteroids for local inflammation of the esophagus and for the prevention of allergy and nausea and vomiting). Other special circumstances need to be communicated to the sponsor. Inhaled or topical steroids and adrenocorticotropic hormone replacement at doses >10mg/day prednisone efficacy dose are permitted if the patient does not have active autoimmune disease;

4. Received an anti-tumour vaccine or received a live vaccine within 4 weeks before the first dose of study treatment;

8. Any active autoimmune disease or history of autoimmune disease (e.g., interstitial pneumonitis, uveitis, enteritis, hepatitis, pituitary gland inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism); Except for patients with vitiligo or those who had asthma or allergies in childhood but did not need any intervention as adults; patients with autoimmune-mediated hypothyroidism treated with stable doses of thyroid replacement hormone and type I diabetes mellitus treated with stable doses of insulin may be included;

9. Diagnosis of immunodeficiency, including positive HIV test, other acquired/congenital immunodeficiency diseases, organ transplantation and allogeneic bone marrow transplantation;

10. Diagnosis of uncontrolled cardiac clinical symptoms or disease such as: a. NYHA II or above heart failure; b. unstable angina; c. myocardial infarction within 1 year; d. clinically significant supraventricular or ventricular arrhythmias requiring clinical intervention;

11. Severe infections (CTCAE > grade 2), such as severe pneumonia requiring hospitalisation, bacteraemia, infectious co-morbidities, etc., within 4 weeks before the first use of study treatment; Baseline chest imaging suggestive of active lung inflammation, signs and symptoms of infection requiring oral or intravenous antibiotic treatment within 2 weeks before the first use of study treatment, except for prophylactic antibiotic use;

12. History of interstitial lung disease or non-infectious pneumonia, or pulmonary insufficiency ≥ grade 3 as confirmed by pulmonary function tests;

13. Active tuberculosis infection detected by history or CT examination, or history of active tuberculosis infection within 1 year before enrollment or more than 1 year previously without regular treatment;

14. Presence of active hepatitis B (HBV DNA ≥ 2000 IU/mL or 104 copies/mL), hepatitis C (hepatitis C antibody positive and HCV-RNA above the lower limit of detection);

15. Presence of abnormal sodium, potassium, and calcium laboratory test values greater than grade 1 within 2 weeks prior to enrollment that do not improve with treatment;

16. Known hypersensitivity to large protein preparations, or to any of the components of camrelizumab, or anaphylaxis, hypersensitivity, or contraindication to paclitaxel or carboplatin or to any of the components used within their preparations;

17. Previously diagnosed with any other malignancy before the first use of the investigational drug, except for malignancies with low risk of metastasis and death (5-year survival rate>90%), such as adequately treated basal cell or squamous cell skin cancer or cervical carcinoma in situ.

18. As judged by the investigator, the subject has other factors that may lead to forced termination of the study midway.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Tianjin Medical University Cancer Institute and Hospital

OTHER

Sponsor Role: lead

Responsible Party

Wencheng Zhang

Associated Prof. in the department of radiation oncology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Wencheng Zhang, M.D.

Role: PRINCIPAL_INVESTIGATOR

Tianjin Cancer Hospital

Xiaofeng Duan, M.D.

Role: PRINCIPAL_INVESTIGATOR

Tianjin Cancer Hospital

Locations

Tianjin Cancer Hospital

Tianjin, Tianjin Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

Wencheng Zhang, M.D.

Role: CONTACT

zhangwencheng@tjmuch.com

02223340123 ext. 1121

Facility Contacts

Wencheng Zhang, M.D.

Role: primary

zhangwencheng@tjmuch.com

02223340123 ext. 1121

Other Identifiers

E20250845A

Identifier Type: -

Identifier Source: org_study_id